| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 227.38% | HC Wainwright & Co. | $6 → $5.5 | Maintains | Buy |
| 11/10/2023 | 138.1% | Piper Sandler | $5 → $4 | Maintains | Overweight |
| 08/28/2023 | 167.86% | Craig-Hallum | → $4.5 | Initiates Coverage On | → Buy |
| 08/09/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/10/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/09/2023 | 257.14% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 01/27/2023 | 197.62% | SVB Leerink | $6 → $5 | Maintains | Outperform |
| 10/21/2022 | 138.1% | Jefferies | → $4 | Assumes | → Buy |
| 04/28/2022 | 286.9% | Craig-Hallum | → $6.5 | Initiates Coverage On | → Buy |
| 03/16/2022 | 257.14% | Mizuho | $8 → $6 | Maintains | Buy |
| 02/16/2022 | 257.14% | SVB Leerink | $8 → $6 | Maintains | Outperform |
| 12/31/2021 | 376.19% | SVB Leerink | $6 → $8 | Maintains | Outperform |
| 12/31/2021 | 221.43% | HC Wainwright & Co. | $4.25 → $5.4 | Maintains | Buy |
| 11/17/2021 | 257.14% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 10/29/2021 | 138.1% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 04/23/2020 | 733.33% | Mizuho | $18 → $14 | Maintains | Buy |
| 02/20/2020 | 971.43% | Mizuho | $22 → $18 | Maintains | Buy |
| 02/18/2020 | 614.29% | Piper Sandler | → $12 | Initiates Coverage On | → Overweight |
| 09/11/2019 | 1209.52% | Mizuho | $27 → $22 | Maintains | Buy |
What is the target price for Xeris Biopharma Holdings (XERS)?
The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $5.50 expecting XERS to rise to within 12 months (a possible 227.38% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Xeris Biopharma Holdings (XERS)?
The latest analyst rating for Xeris Biopharma Holdings (NASDAQ: XERS) was provided by HC Wainwright & Co., and Xeris Biopharma Holdings maintained their buy rating.
When is the next analyst rating going to be posted or updated for Xeris Biopharma Holdings (XERS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Xeris Biopharma Holdings (XERS) correct?
While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a maintained with a price target of $6.00 to $5.50. The current price Xeris Biopharma Holdings (XERS) is trading at is $1.68, which is out of the analyst's predicted range.